Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Summary

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Timeline

Start

2022-05-05

Primary completion

2022-08-22

Completion

2022-09-10

Outcome

Met primary endpoint

registry analysis (superiority test); LNZ101 vs Vehicle Ophthalmic Solution; p <0.0001; Odds Ratio (OR) 34.262; Generalized Estimating Equation (GEE) NCT05294328 ↗

registry analysis (superiority test); LNZ100 vs Vehicle Ophthalmic Solution; p <0.0001; Odds Ratio (OR) 73.443; Generalized Estimating Equation (GEE) NCT05294328 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aceclidine	Small molecule	—	Other
Subject	Brimonidine	Unknown	—	Other

Indications